[F. He and G. MacGregor, Salt, blood pressure and cardiovascular disease, Curr. Opin. Cardiol. 22 (2007) 298-305; DOI: 10.1097/HCO.0b013e32814f1d8c.10.1097/HCO.0b013e32814f1d8c]Search in Google Scholar
[R. Hernandez-Hernandez, B. Sosa-Canache, M. Velasco, M. J. Armas-Hernandez, M. C. Armas-Padilla and R. Cammarata, Angiotensin II receptor antagonists role in arterial hypertension, J. Hum. Hypertens. 16 (2002) S93-99; DOI: 10.1038/sj/jhh/1001352.]Search in Google Scholar
[M. W. Lo, M. R. Goldberg, J. B. McCrea, H. Lu, C. I. Furtek and T. D. Bjornsson, Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans, Clin. Pharmacol. Ther. 58 (1995) 641-649; DOI: 10.1016/0009-9236(95)90020-9.10.1016/0009-9236(95)90020-9]Search in Google Scholar
[H. R. Costantino, L. Illum, G. Brandt, P. H. Johnson and S. C. Quay, Intranasal delivery: physicochemical and therapeutic aspects, Int. J. Pharm. 337 (2007) 1-24; DOI: 10.1016/j.ijpharm.2007.03.025.10.1016/j.ijpharm.2007.03.02517475423]Search in Google Scholar
[M. I. Ugwoke, R. U. Agu, N. Verbeke and R. Kinget, Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives, Adv. Drug Deliv. Rev. 57 (2005) 1640-1665, DOI: 10.1016/j.addr.2005.07.009.10.1016/j.addr.2005.07.00916182408]Search in Google Scholar
[R. Agu and M. Ugwoke, In Situ and Ex Vivo Nasal Models for Preclinical Drug Development Studies, in Drug Absorption Studies in Situ, in Vivo and In Silico Models (Eds. C. Ehrhardt and K. Kim), AAPS Pharmaceutical Press, New York 2008, pp. 112-134; DOI: 10.1007/978-0-387-74901-3_5.10.1007/978-0-387-74901-3_5]Search in Google Scholar
[T. Yang, A. Hussain, J. Paulson, T. J. Abbruscato and F. Ahsan, Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies, Pharm. Res. 21 (2004) 1127-1136; DOI: 10.1023/B:PHAM.0000032998.84488.7a.10.1023/B:PHAM.0000032998.84488.7a]Search in Google Scholar
[T. Seki, H. Kanbayashi, S. Chono, Y. Tabata and K. Morimoto, Effects of a sperminated gelatin on the nasal absorption of insulin, Int. J. Pharm. 338 (2007) 213-218; DOI: 10.1016/j.ijpharm.2007.02.004.10.1016/j.ijpharm.2007.02.00417346909]Search in Google Scholar
[R. U. Agu, S. Valiveti, D. C. Earles, M. Klausner, P. J. Hayden, D. P. Wermeling and A. L. Stinchcomb, Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats, Endocr. Res. 30 (2004) 455-467; DOI: 10.1081/ERC-200035957.10.1081/ERC-200035957]Search in Google Scholar
[N. V. Chemuturi, P. Hayden, M. Klausner and M. D. Donovan, Comparison of human tracheal/bronchial epithelial cell culture and bovine nasal respiratory explants for nasal drug transport studies, J. Pharm. Sci. 94 (2005) 1976-1985; DOI: 10.1002/jps.20404.10.1002/jps.2040416052562]Search in Google Scholar
[R. U. Agu, H. Vu Dang, M. Jorissen, R. Kinget and N. Verbeke, Metabolism and absorption enhancement of methionine enkephalin in human nasal epithelium, Peptides 25 (2004) 563-569; DOI: 10.1016/j.peptides.2004.02.019.10.1016/j.peptides.2004.02.01915165710]Search in Google Scholar
[N. Denora, V. Laquintana, A. Lopedota, M. Serra, L. Dazzi, G. Biggio, D. Pal, A. K. Mitra, A. Latrofa, G. Trapani and G. Liso, Novel L-dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety, Pharm. Res. 24 (2007) 1309-1324; DOI: 10.1007/s11095-007-9255-y.10.1007/s11095-007-9255-y]Search in Google Scholar
[P. K. Yeung, A. Jamieson, G. J. Smith, D. Fice and P. T. Pollak, Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection, Int. J. Pharm. 204 (2000) 17-22; DOI: 10.1016/S0378-5173(00)00453-1.10.1016/S0378-5173(00)00453-1]Search in Google Scholar
[A. Soldner, L. Z. Benet, E. Mutschler and U. Christians, Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers, Br. J. Pharmacol. 129 (2000) 1235-1243; DOI: 10.1038/sj.bjp.0703150.10.1038/sj.bjp.0703150]Search in Google Scholar
[M. D. Ribadeneira, B. J. Aungst, C. J. Eyermann and S. M. Huang, Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption, Pharm. Res. 13 (1996) 227-233; DOI: 10.1023/A:1016086930019.10.1023/A:1016086930019]Search in Google Scholar
[O. von Richter, O. Burk, M. F. Fromm, K. P. Thon, M. Eichelbaum and K. T. Kivistö, Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens, Clin. Pharmacol. Ther. 75 (2004) 172-83; DOI: 10.1016/j.clpt.2003.10.008.10.1016/j.clpt.2003.10.008]Search in Google Scholar
[B. I. Florea, I. C. van der Sandt, S. M. Schrier, K. Kooiman, K. Deryckere, A. G. de Boer, H. E. Junginger and G. Borchard, Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3), Br. J. Pharmacol. 134 (2001) 1555-1563; DOI: 10.1038/sj.bjp.0704390.10.1038/sj.bjp.0704390]Search in Google Scholar
[T. Korjamo, P. Honkakoski, M. R. Toppinen, S. Niva, M. Reinisalo, J. J. Palmgrén and J. Mönkkönen, Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines, Eur. J. Pharm. Sci. 26 (2005) 266-279; DOI: 10.1016/j.ejps.2005.06.004.10.1016/j.ejps.2005.06.004]Search in Google Scholar
[Z. Shao, R. Krishnamoorthy and A. K. Mitra, Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations, Pharm. Res. 9 (1992) 1157-1163; DOI: 10.1023/A:1015847604654.10.1023/A:1015847604654]Search in Google Scholar
[M. A. Bagger, H. W. Nielsen and E. Bechgaard, Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol, Eur. J. Pharm Sci. 14 (2001) 69-74; DOI: 10.1016/S0928-0987(01)00146-4.10.1016/S0928-0987(01)00146-4]Search in Google Scholar